Analyst Price Targets — DRIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2025 12:45 pm | — | Stifel Nicolaus | $16.00 | $10.61 | StreetInsider | DarioHealth Corp. (DRIO) PT Raised to $16 at Stifel Following 20-1 Stock Split |
| November 16, 2022 8:28 am | — | Industrial Alliance Securities | $7.50 | $5.18 | Benzinga | Alliance Global Partners Maintains Buy on DarioHealth, Lowers Price Target to $7.5 |
| August 18, 2022 1:37 am | — | Cowen & Co. | $14.00 | $5.49 | Benzinga | Cowen & Co. Maintains Outperform on DarioHealth, Lowers Price Target to $14 |
| May 16, 2022 8:56 am | — | Cowen & Co. | $18.00 | $6.33 | Benzinga | Cowen & Co. Maintains Outperform on DarioHealth, Raises Price Target to $18 |
Latest News for DRIO
Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Analyst Ratings This is a summary of recent ratings
Phreesia (NYSE: PHR - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 92.1% of Phreesia shares are
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DRIO.
U.S. House Trading
No House trades found for DRIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.